en · de · es · fr · pt
semax-notes.peptides6908.com › Data › Background And Development — Beginner to Advanced

Background And Development — Beginner to Advanced

By Editorial Desk · published 2025-12-02 · last reviewed 2025-12-18 · Data

This is a working overview of nasal drops, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Semax Background and Molecular Structure

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.

Semax at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideAnalog of an ACTH fragment
Amino acid lengthSeven residuesMet-Glu-His-Phe-Pro-Gly-Pro
OriginMoscow, 1980sInstitute of Molecular Genetics
Approved regionsRussia and some neighboring statesNot cleared in Western markets
Common trade namesMultiple national brandsSold as a nasal formulation

Semax Peptide Structure and Origin

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Related pages on this site

Semax Origin and Molecular Structure

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Background and Development History

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax Structure and Research Background

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Background from the literature

=== Anti-mold === In certain cases, a nystatin derivative has been used to prevent the spread of mold on objects such as works of art. For example, it was applied to wood panel paintings damaged as a result of the Arno River Flood of 1966 in Florence, Italy.

In Ethiopia and Zambia, elaborate scarification is often done on women at puberty, used to denote a willingness to be a mother. The markings show that she can stand the pain of childbirth, as well as being an indication of her emotional maturity.

The success of "Upside Down" led to interest from WEA-subsidiary Blanco y Negro Records which signed the group in early 1985. The group released the single "Never Understand" in February which reached number forty-seven on the UK Singles Chart. The label had initially refused to press the single due to its B-side, "Suck", but went ahead given the alternative put forward by the band, a song called "Jesus Fuck". The band were eager to get "Jesus Fuck" released, and McGee got as far as producing test pressings of a re-issue of "Upside Down" with the song on the B-side, before the band insisted that Blanco y Negro include the track on their next single. The follow-up, "You Trip Me Up", was delayed due to staff at the pressing plant refusing to press it due to the presence of the song, now re-titled "Jesus Suck"; The single was released in June 1985 with a new B-side, "Just Out of Reach". John Peel got the band to record a second session for his BBC Radio 1 show in February 1985 (the first was only a few months earlier), and the band also made a TV appearance on Whistle Test in March and The Tube the same year. The third single for Blanco y Negro, "Just Like Honey", released in October, was their biggest hit to date, reaching No. 45. Eager to avoid the violence of earlier gigs and to give an opportunity for their songs to be heard without distortion and feedback, the band planned to perform several unannounced acoustic sets supporting Sonic Youth, but this was abandoned when the plans were leaked. Their debut album, Psychocandy, followed in November that year.

Sources: en.wikipedia.org

Reference notes

== J == Jacobsen epoxidation Jacobsen rearrangement Janovsky reaction Japp–Klingemann reaction Japp–Maitland condensation Jocic reaction Johnson–Claisen rearrangement Johnson–Corey–Chaykovsky reaction Jones oxidation Jordan–Ullmann–Goldberg synthesis Julia olefination, Julia–Lythgoe olefination

"Polish" heroin (also kompot and compote in drug culture slang) is a crude preparation of heroin made from poppy straw. It is an opioid, used recreationally as a psychoactive drug. Poppy straw, like opium, is harvested from the opium poppy (Papaver somniferum). Polish heroin was used mainly in Central and Eastern Europe prior to the dissolution of the Soviet Union and the end of communist control of the countries of the Warsaw Pact or Eastern Bloc. While related to opium, Polish heroin more nearly resembles poppy tea in its impurity, but can be very potent. This drug was also considered by Eastern Bloc addicts to be one of last resort when refined heroin, morphine, or other similar drugs were unavailable, as was often the case during the 1950s through the end of the Soviet era. Illicit drug trafficking and clandestine drug manufacture within the communist-governed nations of Poland, Hungary, Romania, Bulgaria, Russia itself, and others was on a much smaller scale and the supply far more erratic and unreliable compared to that of Western nations. Opium poppies, by contrast, were widely available and relatively inexpensive. The drug has been known as early as the 1940s. The drug in its finished state is a bitter brown fluid looking like tea or cola in color. Polish heroin contains diacetylmorphine (heroin), 6-monoacetylmorphine (active metabolite of heroin), 3-monoacetylmorphine (less-active metabolite of heroin), morphine and small amounts of codeine.

==== Mycosporine-like amino acids ==== Mycosporine-like amino acids are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments.

Sources: en.wikipedia.org

Reference notes

== Description == Lonicera japonica is a twining vine able to climb up to 10 m (33 ft) high or more in trees, with opposite, simple oval leaves 3–8 cm (1+1⁄4–3+1⁄4 in) long and 2–3 cm (3⁄4–1+1⁄4 in) broad. When its stems are young, they are slightly red in color and may be fuzzy. Older stems are brown with peeling bark, and are often hollow on the inside. The flowers are double-tongued, opening white and fading to yellow, and sweetly vanilla scented. The fruit, which is produced in fall, is a black spherical berry 3–4 mm (1⁄8–3⁄16 in) diameter containing a few seeds.

The new 15th district stretches from Hidalgo County in the Rio Grande Valley (including Edinburg and Weslaco), and now extends northeasterly into several rural counties between Corpus Christi, San Antonio and Victoria, including such communities as Falfurrias, Alice, Sinton, Beeville, Cuero and Gonzales. The incumbent is Republican Monica De La Cruz, who was re-elected with 57.1% of the vote in 2024. In 2024, Donald Trump won 58.5% in this overwhelmingly Hispanic district, which gave Ted Cruz 53.5% in the same election (six years after Cruz lost to Beto O'Rourke, who won 55.4% in the 2018 election for the same Senate seat). Hillary Clinton won the district with 55% in 2016 before it flipped to Trump (who won 50.7%) in 2020.

== Development == In early embryogenesis, the esophagus develops from the endodermal primitive gut tube. The ventral part of the embryo abuts the yolk sac. It is very small in the beginning, but it lengthens due to descent of lungs and heart. During the second week of embryological development, as the embryo grows, it begins to surround parts of the sac. The enveloped portions form the basis for the adult gastrointestinal tract. The sac is surrounded by a network of vitelline arteries. Over time, these arteries consolidate into the three main arteries that supply the developing gastrointestinal tract: the celiac artery, superior mesenteric artery, and inferior mesenteric artery. The areas supplied by these arteries are used to define the midgut, hindgut and foregut. The surrounded sac becomes the primitive gut. Sections of this gut begin to differentiate into the organs of the gastrointestinal tract, such as the esophagus, stomach, and intestines. The esophagus develops as part of the foregut tube. The esophagus develops as a tube, lined with smooth muscle but continues development craniocaudally into different proportions of striated muscle. Both types of muscle have been demonstrated to be of different precursor cells. The innervation of the esophagus develops from the pharyngeal arches.

Euromac, an EU-funded consortium of medical and research institutes across Europe which is building a patient registry and raising standards of care for people with McArdle Disease. Archived 2021-04-22 at the Wayback Machine International Association for Muscle Glycogen Storage Disease (IamGSD). Walking With McArdle's - IamGSD videos EUROMAC Introduction - Video about McArdle disease and the EUROMAC Registry of McArdle disease and other rare glycogenoses patients

Sources: en.wikipedia.org

Frequently asked questions

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Is Semax an approved medication anywhere?

It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.

What is the relationship to ACTH?

Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.

What is the amino acid sequence of Semax?

The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.

Network